Basic Information
| LncRNA/CircRNA Name | DGCR9 |
| Synonyms | NA |
| Region | GRCh38_22:19017834-19020248 |
| Ensemble | ENSG00000273032 |
| Refseq | NR_024159 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR etc. |
| Sample | gastric cancer tissues, cell lines (GES-1, AGS, MGC803, HGC27, and SGC7901) |
| Expression Pattern | up-regulated |
| Function Description | DGCR9 was shown to have increased expression in gastric cancer tissues and in gastric cancer cell lines. Further, DGCR9 was found to be associated with clinicopathological characteristics of patients with gastric cancer. In particular, DGCR9 was positively associated with lymph node invasion and tumor-node-metastasis (TNM) stage in gastric cancer patients. By in vitro functional analysis, knockdown of DGCR9 in gastric cancer cells suppressed cellular proliferation, migration, and glucose uptake. In contrast, overexpression of DGCR9 increased each of these cancer cell characteristics. |
| Pubmed ID | 29719408 |
| Year | 2018 |
| Title | Role of DiGeorge syndrome critical region gene 9, a long noncoding RNA, in gastric cancer. |
External Links
| Links for DGCR9 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |